A session, sponsored by Alvimedica Medical Technologies, discussing treatment options for percutaneous coronary intervention (PCI) in diabetic patients, took place at EuroPCR (16-20th May 2016, Paris, France).
The session was the trigger for an exciting discussion on the best ways to improve PCI clinical outcome in diabetic patients, potentially provided by the unique Amphilimus eluting polymer-free drug-eluting stent Cre8.
Stefan Verheye and Eric Eeckhout, chairman and co-chairman of the TNT session, challenged Didier Tchetche and Nicolas Dumonteil, who performed the live case, to explain all the steps and decisions they took in best treating an elderly diabetic patient with multi-lesion disease involving a bifurcation (Medina 1:1:1).
Their choices and techniques led to an excellent result. The operator utilised POT and TAP techniques to tackle this bifurcation which coupled with the Cre8 stent, its cell design, radiopaque markers and zero foreshortening resulted in an optimal outcome.
After the live case Tobert Byrne discussed the efficacy of the “–olimus” drugs in diabetics and how a diabetic patient requires specific technologies in order to overcome the diabetic cell resistance to standard “-olimus” drugs which results in lower efficacy.
Gennaro Sardella presented the latest clinical outcomes for Cre8 in regards to efficacy in diabetic patients. The results of these data, according to a company press release, show that Cre8 has very consistent results when it comes to efficacy endpoints for diabetics that are similar to those of the general population and which are not seen in studies done with other drug eluting stents.
In-stent late lumen loss in diabetic patients at six to nine months was 0.12, 0.14 and 0.16 in the NEXT, Reservoir and pARTicip8 studies respectively.
Target lesion revascularisation at one year of 1.4% in both the Investig8 and pARTicip8 studies. Sardella followed up by claiming that Cre8 is not just an efficacy-oriented stent for diabetics, but also a stent which is very safe. The patient had been administered only three months of DAPT following Cre8 implantation due to a previous history of bleeding. He also explained the design of the on-going ReCre8 study which is an all-comer study with one month DAPT in elective PCI patients and 12 month DAPT in ACS patients comparing Cre8 with Resolute.
Antonio Colombo, from San Raffaele hospital in Milan, says: “If there is a drug-eluting able to bring efficacy in diabetics to a new level, this is Cre8. I foresee that this will be proven in the near future.”